Immunocellular Therapeutics LTD (IMUC) financial statements (2023 and earlier)

Company profile

Business Address 30721 RUSSELL RANCH ROAD
WESTLAKE VILLAGE, CA 91362
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments6,63011,43722,60423,22227,64626,217
Cash and cash equivalents6,63011,43722,60423,22227,64626,217
Prepaid expense 1,1861,159  
Prepaid expense and other current assets715
Other current assets3797917971,220763
Total current assets:7,00913,41524,56124,44228,41026,931
Noncurrent Assets
Property, plant and equipment1110181476676
Prepaid expense 1,3101,116  
Deposits noncurrent assets 1,9564,176  12
Deferred costs  49106  
Other noncurrent assets   583465
Other undisclosed noncurrent assets 100    
Total noncurrent assets:13,4755,52273653188
TOTAL ASSETS:7,00916,89030,08225,17928,94127,019
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,3613,2392,2691,2891,4021,098
Accounts payable1,7751,3421,161322861733
Accrued liabilities29678731863318456
Employee-related liabilities2911,110790335357309
Total current liabilities:2,3613,2392,2691,2891,4021,098
Noncurrent Liabilities
Other undisclosed noncurrent liabilities 7,5196,093   
Total noncurrent liabilities: 7,5196,093   
Total liabilities:2,36110,7588,3621,2891,4021,098
Stockholders' equity
Stockholders' equity attributable to parent, including:4,6486,13221,72023,29226,47423,068
Common stock409665
Additional paid in capital121,088102,35595,84984,63278,43766,232
Accumulated deficit(116,444)(96,223)(74,138)(61,347)(51,969)(43,169)
Warrants and rights outstanding   5981,0652,853
Other undisclosed stockholders' equity attributable to parent   (598)(1,065)(2,853)
Total stockholders' equity:4,6486,13221,72023,29226,47423,068
Other undisclosed liabilities and equity   5981,0652,853
TOTAL LIABILITIES AND EQUITY:7,00916,89030,08225,17928,94127,019

Income statement (P&L) ($ in thousands)

12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Gross profit:    (720)(99)
Operating expenses(21,153)(24,112)(15,513)(9,859)(8,740)(11,728)
Operating loss:(21,153)(24,112)(15,513)(9,859)(9,460)(11,827)
Nonoperating income (expense)
(Investment Income, Nonoperating)
53,8372,945544660(2,271)
Interest and debt expense6,837(1,312)(134)   
Other undisclosed loss from continuing operations before equity method investments, income taxes     (397)
Loss from continuing operations before equity method investments, income taxes:(14,312)(21,587)(12,702)(9,315)(8,801)(14,495)
Other undisclosed loss from continuing operations before income taxes (499)(89)(63)  
Net loss attributable to parent:(14,312)(22,086)(12,791)(9,378)(8,801)(14,495)
Other undisclosed net loss available to common stockholders, basic(3,370)     
Net loss available to common stockholders, diluted:(17,682)(22,086)(12,791)(9,378)(8,801)(14,495)

Comprehensive Income ($ in thousands)

12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net loss:(14,312)(22,086)(12,791)(9,378)(8,801)(14,495)
Comprehensive loss, net of tax, attributable to parent:(14,312)(22,086)(12,791)(9,378)(8,801)(14,495)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: